MARKET

CYTK

CYTK

Cytokinetics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

25.57
-0.36
-1.39%
After Hours: 25.57 0 0.00% 16:43 05/17 EDT
OPEN
25.70
PREV CLOSE
25.93
HIGH
26.18
LOW
25.41
VOLUME
392.17K
TURNOVER
--
52 WEEK HIGH
30.14
52 WEEK LOW
14.71
MARKET CAP
1.83B
P/E (TTM)
-12.3342
1D
5D
1M
3M
1Y
5Y
Cytokinetics Post-Hoc Data Suggests Omecamtiv Mecarbil Works Better In High-Risk Patients For Heart Failure
Benzinga · 5h ago
Cytokinetics Announces Secondary Analysis of GALACTIC-HF Presented in Late Breaking Clinical Trial Session at the American College of Cardiology 70th Annual Scientific Session and Published in the Journal of American College of Cardiology
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that data from a secondary analysis of GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure) assessing the effect of omecamtiv mecarbil ...
GlobeNewswire · 10h ago
Cytokinetics Announced Presentations Related to Health Economics and Outcomes Research in Heart Failure and Hypertrophic Cardiomyopathy at ACC Expo
Cytokinetics, Incorporated (NASDAQ: CYTK) today announced that new findings from analyses of claims data and electronic health records related to heart failure (HF) and hypertrophic cardiomyopathy (HCM) were shared in two poster presentations at the Americ...
Benzinga · 1d ago
Cytokinetics Announces Presentations Related to Health Economics and Outcomes Research in Heart Failure and Hypertrophic Cardiomyopathy at American College of Cardiology 70th Annual Scientific Session & Expo (ACC.21)
Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that new findings from analyses of claims data and electronic health records related to heart failure (HF) and hypertrophic cardiomyopathy (HCM) were shared in two poster presentations at the Americ...
GlobeNewswire · 1d ago
Spinal Muscular Atrophy Treatment Market Trend, Segmentation and Opportunities Forecast To 2028
May 12, 2021 (AmericaNewsHour) -- Research Nester published a report titled “Spinal Muscular Atrophy Treatment Market: Global Demand Analysis &...
AmericaNewsHour · 5d ago
--Mizuho Securities Adjusts Cytokinetics' Price Target to $36 From $26, Maintains Buy Rating
MT Newswires · 6d ago
Analysts Offer Insights on Healthcare Companies: Cytokinetics (CYTK), Revance Therapeutics (RVNC) and FibroGen (FGEN)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Cytokinetics (CYTK), Revance Therapeutics (RVNC) and
SmarterAnalyst · 6d ago
Revenue Downgrade: Here's What Analysts Forecast For Cytokinetics, Incorporated (NASDAQ:CYTK)
Today is shaping up negative for Cytokinetics, Incorporated ( NASDAQ:CYTK ) shareholders, with the analysts delivering...
Simply Wall St. · 6d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CYTK. Analyze the recent business situations of Cytokinetics through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 11 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average CYTK stock price target is 32.64 with a high estimate of 50.00 and a low estimate of 21.00.
EPS
Institutional Holdings
Institutions: 257
Institutional Holdings: 78.56M
% Owned: 109.51%
Shares Outstanding: 71.74M
TypeInstitutionsShares
Increased
37
4.62M
New
23
516.66K
Decreased
42
721.42K
Sold Out
13
661.41K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.79%
Pharmaceuticals & Medical Research
+0.65%
Key Executives
Chairman/Independent Director
Leonard Patrick Gage
Non-Executive Chairman/Independent Director
Leonard Gage
Chief Executive Officer/President/Director
Robert Blum
Chief Financial Officer/Senior Vice President
Ching Jaw
Chief Human Resource Officer/Chief Administrative Officer
David Cragg
Executive Vice President
Andrew Callos
Executive Vice President
Fady Malik
Chief Accounting Officer/Vice President
Robert Wong
Senior Vice President/General Counsel/Secretary
Mark Schlossberg
Independent Director
Muna Bhanji
Independent Director
Robert Califf
Independent Director
Santo Costa
Independent Director
John Henderson
Independent Director
Edward Kaye
Independent Director
B. Lynne Parshall
Independent Director
Sandford Smith
Independent Director
Wendall Wierenga
Independent Director
Wendell Wierenga
Independent Director
Nancy Wysenski
No Data
  • All
  • Financials
  • Insiders
More
About CYTK
Cytokinetics Inc. is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions. The Company is developing small molecule drug candidates, which are specifically engineered to enhance muscle function and contractility. Its lead drug candidates in clinical development are: omecamtiv mecarbil, a cardiac myosin activator; AMG 594, a cardiac troponin activator; reldesemtiv, a fast-skeletal muscle troponin activator (FSTA) and CK-3773274 (CK-274), a cardiac myosin inhibitor.

Webull offers kinds of Cytokinetics, Inc. stock information, including NASDAQ:CYTK real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CYTK stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CYTK stock methods without spending real money on the virtual paper trading platform.